top of page

The Future of Women’s Health: Transforming Diagnostics with Glycoform Biomarkers.

Writer's picture: Michelle HillMichelle Hill

Updated: Jan 9


A woman with scientific illustrations

Revolutionizing women’s health with glycoform biomarker technology that promises earlier, more accurate diagnoses for gynecological diseases and cancers.


Introduction

Early detection saves lives. For instance, the 5-year relative survival rate for women diagnosed with localized (early-stage) ovarian cancer is 93% (cancer.org) . Timely and accurate diagnosis of gynecological diseases and cancers can significantly improve outcomes. Enter glycoform biomarkers, a cutting-edge innovation powered by glycoproteomics. This technology is reshaping diagnostics, offering unparalleled precision in identifying disease-specific protein alterations.

In this blog, we delve into the transformative potential of glycoform biomarker research, spotlighting its impact on women’s health and its role in shaping the future of diagnostic medicine.

 

What Are Glycoform Biomarkers and Why They Matter in Women’s Health

Glycoform biomarkers are unique molecular structures important in disease development, and a topic of the latest scientific breakthroughs. Glycoproteins are proteins with sugars attached. The different types of sugar attachments are determined by the glycosylation machinery in cell which produces the glycoprotein. Glycosylation is the process where sugars are attach to new proteins. Different glycosylation leads to different glycoforms, which has different protein functions.


Three major applications of glycoform biomarkers in women’s health are:

  1. Ovarian Cancer Detection: Current tests like CA-125 lack the sensitivity required for early detection, leading to late-stage diagnoses in most cases. However, recent studies have identified abnormal glycosylation and specific glycoforms of CA125 as unique features which could enhance differential diagnosis of the disease. (Gyne Onc; J Ov Res; Comm Biol). Besides CA125, glycosylation changes on other proteins have been observed, with potential to be biomarkers. For example, studies have identified altered glycosylation of immune system protein in ovarian cancer patients (Comm Biol).


  2. Endometriosis Diagnosis: Glycoforms are also being explored as non-invasive biomarkers for endometriosis, a condition often misdiagnosed or diagnosed too late for effective treatment (J Adv Res).


  3. Personalized Medicine: Glycoform analysis provides insights into disease progression and patient-specific glycosylation patterns, paving the way for personalized medicine. Studies have revealed that alterations in glycosylation can modulate inflammatory responses, enable immune escape, promote cancer metastasis, and regulate apoptosis (Nature Rev Nephrol). Furthermore, glycosylation patterns are influenced by genetic, environmental, and metabolic factors, emphasizing their critical role in personalized healthcare strategies (JACS Au).


How the LeMBA-MS Platform Revolutionizes Biomarker Discovery

Single biomarkers often fail to capture the diverse and complex disease patterns seen in human populations, as variability in both tumors and individuals frequently limits the sensitivity and specificity of single markers (IARC). This limitation underscores the need for new, validated biomarker panels to address unmet diagnostic needs. An ideal glycoform biomarker technology must also facilitate rapid translation to clinical tests, enabling timely and accurate diagnostics for conditions like ovarian cancer.


ProSeek Bio's Lectin Magnetic Bead Array-Mass Spectrometry (LeMBA-MS) platform addresses a critical need in translational research by enabling the timely discovery and validation of glycoform biomarkers. This technology facilitates the simultaneous monitoring of multiple biomarker glycoforms, encompassing both protein and glycosylation variations, within a single assay. By employing a one-step sample processing method directly from blood samples, LeMBA-MS overcomes traditional challenges associated with the high complexity of proteomics, thereby streamlining the development of straightforward blood tests (Springer Nature).


A notable application of the LeMBA-MS platform is demonstrated in a study by Dutt et al. (Prot Clin App), which focused on the discovery and validation of serum glycoprotein biomarkers for high-grade serous ovarian cancer (HGSOC). The research identified a panel of glycoforms with significant potential for early detection of HGSOC, underscoring the platform's efficacy in advancing diagnostic capabilities for ovarian cancer .


 

Broader Applications and Benefits

The implications of glycoform biomarker technology extend beyond diagnostics:

  • Improved Prognosis: Early detection facilitates timely treatment, reducing mortality rates.

  • Cost-Effectiveness: Non-invasive tests like these lower healthcare costs by avoiding unnecessary surgeries and treatments.

  • Patient-Centric Care: Blood-based tests align with the growing demand for patient-friendly diagnostic solutions.

 

Challenges and Future Directions

The following challenges need to be addressed to fully realise the promise of glycoform biomarkers:

  • Validation and Standardization: Large-scale clinical trials are required to validate findings and establish standardized protocols.

  • Integration into Healthcare Systems: Widespread adoption necessitates awareness among clinicians and support from regulatory bodies.

  • Affordability: Ensuring these advanced tests remain cost-effective is crucial for global impact.


Key Takeaways

  1. Revolutionizing Women’s Health Diagnostics: Discover how glycoform biomarkers enable early and accurate detection of ovarian cancer and endometriosis.


  2. Cutting-Edge Technology: Learn how the LeMBA-MS platform simplifies blood tests, accelerating biomarker discovery and clinical application.


  3. Non-Invasive Testing for Better Outcomes: Explore the potential of glycoform biomarkers to reduce diagnostic delays and improve patient care.


  4. Personalized Medicine Breakthroughs: Understand how glycoform analysis unlocks personalized treatments based on unique glycosylation patterns.


  5. Addressing Unmet Needs: See how glycoproteomics is addressing gaps in women’s health diagnostics with validated biomarker panels.

 

In an era where precision medicine is reshaping healthcare, glycoform biomarkers stand out as a beacon of hope for millions of women worldwide. By addressing long-standing diagnostic challenges, this technology ensures that no woman’s health concerns go undetected or untreated.


 

Comments


©2024 by ProSeek Bio Pty Ltd (ABN 76 671 418 401).

bottom of page